Table 5.
Odds ratios for breast cancer according to total “exclusive use” of each individual high inhibitor antidepressant agent.
| No. of SSRI prescriptionsa | Casesb N = 2129 n | (%) | Controlsb N = 21297 n | (%) | Unadjusted ORc (95% CI) | Adjusted ORd (95% CI) |
|---|---|---|---|---|---|---|
| No usee | 1783 | (83.8) | 17908 | (84.1) | 1.00 (Reference) | 1.00 (Reference) |
| Paroxetine | ||||||
| 1–23 | 69 | (3.2) | 629 | (3.0) | 1.10 (0.86, 1.42) | 1.09 (0.85, 1.41) |
| ≥24 | 15 | (0.7) | 131 | (0.6) | 1.15 (0.67, 1.97) | 1.13 (0.66, 1.93) |
| Sertraline | ||||||
| 1–23 | 37 | (1.7) | 295 | (1.4) | 1.26 (0.89, 1.78) | 1.26 (0.89, 1.78) |
| ≥24 | 12 | (0.6) | 66 | (0.3) | 1.83 (0.99, 3.39) | 1.83 (0.99, 3.40) |
| Fluoxetine | ||||||
| 1–23 | 48 | (2.3) | 613 | (2.9) | 0.79 (0.58, 1.06) | 0.79 (0.58, 1.06) |
| ≥24 | 14 | (0.7) | 167 | (0.8) | 0.84 (0.49, 1.46) | 0.83 (0.48, 1.44) |
OR, odds ratio(s); CI, confidence intervals.
aSSRI (selective serotonin reuptake inhibitor) use anytime during follow-up 2 or more years prior to index date where the number of prescriptions dispensed approximates the number of months exposed.
b151 cases and 1488 controls who were not exclusive users of one agent were not included in this analysis.
cMatched on age in 5-year age groups but unadjusted for the influence of other risk factors.
dAdjusted for age at index (years), marital status, income support status, residence status, and use of oral contraceptives and/or use of hormone therapy.
e“No use” (reference category) refers to women with no SSRI prescriptions dispensed 2 or more years prior to index date. Subjects may have filled prescription(s) for SSRIs during the 2 years prior to index date which was not considered to be etiologically relevant.
Percentages may not add up to 100% due to rounding.